RxDoctor Payments Data

Nicholas Brockert, MD

Family Medicine · Lansing, KSNPI 1447494216

Payments from drug & device makers

$4,650in general payments, 2019–2025

Across 298 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$688
  • AbbVie$660
  • Boehringer Ingelheim$397
  • Abbott$325
  • Novo Nordisk$300
  • Lilly USA, LLC$295
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,650 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$295,137
Medicare patients
763
Services billed
4,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$109,334
EliquisApixaban129$88,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$57,698
JanuviaSitagliptin Phosphate54$56,468
JardianceEmpagliflozin53$50,560
XifaxanRifaximin13$49,295
XareltoRivaroxaban35$41,948
RybelsusSemaglutide31$40,907
GemtesaVibegron23$19,321
Spiriva RespimatTiotropium Bromide32$18,516
MounjaroTirzepatide17$17,863
LinzessLinaclotide15$15,865
MyrbetriqMirabegron14$15,423
TrulicityDulaglutide13$14,348
Breo ElliptaFluticasone/Vilanterol20$14,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$300$150,241127 claims
PfizerEliquis$688$88,111129 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$397$75,16998 claims
GSKTrelegy Ellipta, Breo Ellipta$191$71,71587 claims
MerckJanuvia$116$56,46854 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$65$49,29513 claims
Johnson & JohnsonXarelto$171$41,94835 claims
Lilly USA, LLCMounjaro, Trulicity$295$32,21130 claims
Sumitomo Pharma America, Inc.Gemtesa$15$19,32123 claims
AbbVieLinzess$660$15,86515 claims
Astellas Pharma US IncMyrbetriq$47$15,42314 claims
AstraZenecaByetta$236$9,19711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Lansing

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →